In the course of our search for natural estrogenic compounds from medicinal plants, we found that the methanolic extract from the roots of Moghania philippinensis (Fabaceae) showed significant effects on the proliferation of MCF-7 cells (human breast cancer) and induction of b b-galactosidase activity in a yeast two-hybrid assay. Through estrogenic activity-guided fractionation, we isolated several active flavonoids including prenylated ones. The CHCl 3 fraction and its new constituent, 8-(1,1-dimethylallyl)genistein (9) , appreciably increased the uterine weight in ovariectomized rats when administered orally for 14 consecutive days, in which compound 9 showed stronger estrogenic activity than genistein. Antiestrogenic activities were also examined based on the inhibition of MCF-7 cell proliferation and b b-galactosidase activity in the yeast two-hybrid assay, mediated by 17b bestradiol. 5,7,3,4-Tetrahydroxy-6,8-diprenylisoflavone (6) showed the strongest antiestrogenic activity.
In recent years there has been increasing interest in hormone replacement therapy (HRT), which seems to protect women against hot flashes, reduced bone density, cardiovascular problems, and osteoporosis. 1) On the other hand, synthetic estrogen replacement therapy was reported to increase the risk of certain types of cancer, such as endometrial and breast cancer.
2) Since a variety of plants and vegetables were shown to exert beneficial effects on the above-mentioned estrogen mediated diseases, 3) many phytoestrogens, such as isoflavones, coumestans, resorcyclic acid lactones, and dihydroxychalcones have been isolated. 4) Ichikawa et al. 5) have recently reported that 4,4Ј-dihydroxy-2,6-dimethoxydihydrochalcone (retrodihydrochalcone) and 5,7-dihydroxy-3-(4-hydroxybenzyl)-4-chromanone (homoisoflavone) from the stem wood of Dracaena loureiri exhibited significant estrogenic activity.
In a search for new phytoestrogens that are effective in preventing and treating estrogen-mediated diseases, we examined many medicinal plants for their estrogenic activity. Of these, a methanolic extract of the roots of Moghania philippinensis was demonstrated to have potent estrogenic activity. M. philippinensis (Fabaceae) is a shrubby herb mainly growing in southwestern China. Its roots have traditionally been used for the treatment of menopausal syndrome, leukorrhea, rheumatism, arthropathy, and improving bone mineral density. 6, 7) In the present paper, we report estrogenic and antiestrogenic activities of the constituents of M. philippinensis, as monitored in two independent in vitro estrogen assay systems: the estrogen-dependent proliferation of MCF-7 (human breast cancer) cells and a yeast two-hybrid assay developed by Nishikawa et al. 8) Furthermore, we investigated the estrogenic effect induced by oral administration of the extract of M. philippinensis, 8-(1,1-dimethylallyl)genistein (9) and genistein (1) in ovariectomized (OVX) rats. Plant Material The roots of M. philippinensis were obtained from Nanning, Guangxi Province, China, in March 2002 and the botanical source was identified by Dr. Katsuko Komatsu, Toyama Medical and Pharmaceutical University (TMPU). A voucher specimen (TMPU 19843 ) was deposited at the Institute of Natural Medicine, TMPU, Toyama, Japan.
MATERIALS AND METHODS

Materials
Extraction and Fractionation Procedures
The pulverized roots of M. philippinensis (2.5 kg) were extracted with MeOH under reflux (5 lϫ3) for 3 h. The combined solutions were evaporated to dryness in vacuo to give a MeOH-soluble fraction. The MeOH-soluble fraction (127.1 g) was suspended in 90% MeOH (1.5 l) and extracted with hexane (1 lϫ3). The hexane phase was evaporated to dryness to give a hexane-soluble fraction (MH, 19.9 g). The residual MeOH solution was concentrated in vacuo to give a residue (107.2 g), which was suspended in 1 l of water and then extracted with CHCl 3 (800 mlϫ3). The combined solutions were evaporated to dryness to give a CHCl 3 Fig. 1) were iso-lated from a CHCl 3 -soluble fraction (MC) of M. philippinensis through bioassay-guided fractionation, as reported in the previous paper. 9) Compound 9 was synthesized from genistein by a method described in previous papers 9, 10) and used for the in vivo experiment. The purity of the compound was more than 98%, as determined based on the 1 H-NMR spectrum and HPLC.
MCF-7 Cell Proliferation Assay Estrogen-sensitive human MCF-7 breast cells were grown in DMEM supplemented with 5% FBS, penicillin, and streptomycin. The cells were harvested by trypsinization (0.25% trypsin) and plated at a concentration of 5ϫ10 3 cells/well in DMEM supplemented with 5% FBS in 96-well tissue culture plates (Iwaki, Co., Chiba, Japan) and allowed to attach for 24 h. Then the culture medium was replaced with phenol red-free DMEM containing 10% heat-inactivated dextran/charcoal-stripped (DC) human serum prior to the addition of compounds.
11)
Stock solutions of test compounds in DMSO were diluted with DC medium. The final DMSO concentration in culture medium did not exceed 0.1%, and this concentration did not affect cell viability. After 4 d in a humidified incubator with 5% CO 2 at 37°C, the growth of the cells was measured using the MTT method.
12)
Yeast Two-Hybrid Assay The yeast two-hybrid assay was carried out according to the method of Nishikawa et al. 8) Briefly, yeast cells expressing estrogen receptor a (ERa) was grown overnight at 30°C with shaking in synthetic defined (SD) medium lacking tryptophan and leucine. Yeast cells were treated with a test compound for 4 h at 30°C, and bgalactosidase activity was determined as follows. The growth of the yeast cells was monitored by measuring the turbidity at 600 nm. The treated yeast cells were collected by centrifugation (8000ϫg, 5 min) and resuspended in 200 ml of Z-buffer (0.1 M sodium phosphate, pH 7.0, 10 mM KCl, and 1 mM MgSO 4 ) containing 1 mg/ml of zymolyase at 37°C for 15 min. The reaction was started by the addition of 40 ml of 4 mg/ml ONPG as a substrate. When the yellow color developed (incubation time: t), 100 ml of 1 M Na 2 CO 3 was added to stop the reaction. The absorbance of solution (150 ml) was measured at 420 and 550 nm. b-Galactosidase activity (U) was determined using the following formula:
Antiestrogen Assay To examine antagonistic activity of compounds, the inhibition of b-galactosidase activity and the growth of MCF-7 cells, which had been induced by 10 Ϫ7 and 10 Ϫ10 M 17b-estradiol, respectively, were measured at various concentrations of test compounds.
Uterotrophic Assay Female Sprague-Dawley rats (10-11 weeks old, 210-220 g) rats were purchased from Nippon SLC Co. (Shizuoka, Japan). All rats were allowed free access to water and pelleted commercial diet (MM-3, Funabashi Farm) during the experimental period. The light/dark cycle was 12 h light and 12 h dark. The room temperature and humidity were controlled automatically. All rats were OVX or sham-operated by the supplier (Nippon SLC) 1 week before treatment, and randomly divided into groups of 5 rats each: (1) sham, sham-operated (treated with 10% DMSO), (2) bilaterally OVX (treated with 10% DMSO), (3) OVXϩGen (treated with 8 mg/kg of genistein), (4) OVXϩcompound 9 (treated with 2 mg/kg or 10 mg/kg of 9), and (5) OVXϩMC (treated with 200 mg/kg of a CHCl 3 -soluble fraction). All treatments were given by oral gavage for 14 d. On days 15, urine samples were collected using metabolic cages for the measurement of the bone resorption marker deoxypyridinoline (DPD). The animals were weighed and killed 24 h after the last treatment. The uterus, spleen, and thymus were quickly removed and weighed. Bone Turnover Assays DPD (a marker of bone metabolism) is released and excreted in the urine during the process of bone resorption, 13) and the amount was measured using an enzyme immunoassay provided by BML Co. (Tokyo, Japan).
Statistical Analysis Each set of experiments was repeated at least three times. Values are expressed as meanϮ S.E.M. One-way analysis of variance followed by Dunnett's test was used for statistical analysis.
RESULTS
Estrogenic Activity of M. philippinensis Extracts The
MeOH extract of the roots of M. philippinensis was subjected to fractionation by solvent extraction followed by column chromatography on Diaion HP-20 to give five fractions. These fractions were evaluated for their estrogenic activity at various concentrations (Table 1) depending on the assay system. The CHCl 3 -soluble (MC) and MeOH-eluted (MM 1 ) fractions were active in an MCF-7 cell proliferation assay (ca. 160-200% of control) at concentrations of 1 and 10 mg/ml and the yeast two-hybrid assay (ca. 170-450 U at 10 and 100 mg/ml). The 50% MeOH-eluted (MM 2 ) fraction including a flavonoid glycoside genistin (data not shown) increased the growth of MCF-7 cells at the high concentration of 10 mg/ml, but was inactive in the yeast two-hybrid assay. The other extracts showed no or weak estrogenic activity.
Although the weights of uteri in the OVX rats were significantly decreased 14 d after ovariectomization when compared with those of control rats (sham) (Table 2), the weights were increased by consecutive oral administration of the MC fraction at a dose of 200 mg/kg/d (pϽ0.05).
Estrogenic and Antiestrogenic Activities of Isolated Compounds Using an MCF-7 cell-proliferating assay method, all the compounds isolated from a chloroform fraction of M. philippinensis were tested for their estrogenic activities at various concentrations. Under the conditions where 17b-estradiol (positive control) 14) showed the maximum proliferation of cells at a concentration of 10 Ϫ10 M (data not shown), genistein (1), biochanin A (2), 2Ј-hydroxygenistein (3), lupinalbin A (4), and 3Ј-O-methylgenistein (5) stimulated cell proliferation in a concentration-dependent manner ( Fig. 2A) , suggesting that these isoflavonoids are agonistic for estrogen receptors. Similarly, 8-(1,1-dimethylallyl)genistein (9) and 5,7,3Ј-trihydroxy-2Ј-(3-methylbut-2-enyl)-4Ј,5Ј-(3,3-dimethylpyrano)isoflavone (11) showed significant cellproliferating activity at a concentration of 10 Ϫ5 M, at which the potency of 9 (cell-proliferating activity 186% of control) is comparable to that of 1 (196%) (Fig. 2B) . On the other hand, auriculasin (7), flemiphilippinin A (8), and 5,7,3Ј,4Ј-tetrahydroxy-2Ј,5Ј-di(3-methylbut-2-enyl)isoflavone (10) did not show any substantial cell-proliferating activity at concentrations of less than 10 Ϫ5 M. The proliferating activity of a flavanone [(2S)-liquiritigenin (12)], and isoflavanone isoferreirin (16) was also observed at concentrations of more than 10 Ϫ6 M (Fig. 2C ).
In the yeast two-hybrid assay (Fig. 3) , appreciable induction of b-galactosidase activity was observed for genistein (1), 2Ј-hydroxygenistein (3), lupinalbin A (4), and (2S)-liquiritigenin (12) at a concentration of 10 Ϫ4 M. The other isoflavones 2, 5, and 16 showed weak estrogenic activity, but the prenylated isoflavones (6-11, 14, 15) did not show induction of b-galactosidase activity.
As shown in Fig. 4 , under the conditions when tamoxifen (an antagonist of estradiol) inhibited the 17b-estradiol-mediated proliferation of MCF-7 cells by 16%, 2Ј-hydroxygenistein (3) inhibited the proliferation by 17% at a concentration of 10 Ϫ6 M. Prenylated flavonoids 6-9 and 11 inhibited the proliferation of the MCF-7 cells stimulated by 17b-estradiol (15-35% inhibition at concentrations of 10 Ϫ7 -10 Ϫ5 M). Of these, flemiphilippinin A (8) showed greater antagonistic activity (35% inhibition compared with control) than tamoxifen (16% inhibition at the same concentration). These findings show that prenylated flavonoids inhibit the proliferation of MCF-7 cells mediated by 17b-estradiol.
Similarly, using the yeast two-hybrid assay, antagonistic activities of the isolated compounds were determined under the conditions at which these compounds did not inhibit the growth of cells due to cytotoxic effects. Inhibition of the induced b-galactosidase activity was observed for 2 (43% inhibition) and 4 (39% inhibition) (Fig. 5A) . Most of the prenylated flavonoids 6-11 appreciably inhibited the induction of b-galactosidase (Fig. 5B) . At a concentration of 10 Ϫ4 M, 6 Table 3 shows the effects of 1 and 9, which showed the most potent proliferative activity against MCF-7 cells, on the uterine weight in OVX rats. The uterine weights were markedly reduced in OVX rats compared with those of sham-operated rats. However, following oral administration of 1 and 9 for 14 d, the uterine weights were significantly increased at doses of 8 mg/kg and 10 mg/kg (equivalent on a molar basis) by 121% and 130%, respectively. Furthermore, an increasing effect was also observed at the lower dose of 2 mg/kg of 9, when the uterine weight increased by 124% in comparison with that of controls (OVX).
The size of the thymus gland and spleen are influenced by sex hormones in male mice. 15) Ovariectomy leads to an increase in thymus weight and cellularity. Exposure to endogenous estrogen during pregnancy, 16) or treatment with exogenous sex hormone causes massive atrophy of the thymus. 17, 18) In the present experiment, oral administration of compounds 1 and 9 showed no effects on thymus and spleen weights. Ovariectomy caused a significant increase in urinary DPD (Table 4) , but oral administration of 1 and 9 tended to attenuate the decrease in urinary DPD levels in OVX rats.
DISCUSSION
In the present study, we examined the extract and its fractions of M. philippinensis together with isolated compounds for their estrogenic/antiestrogenic activities. The isolation of active constituents was achieved by monitoring the proliferation of MCF-7 cells and the yeast two-hybrid assay. In the MCF-7 cell proliferation assay, the cells show wide variation in regard to their sensitivity to estradiol. 19) Furthermore, since proliferation of MCF-7 cells can be influenced not only by estrogens but also by cytokinins, growth factors, mito- gens, and nutrients, it is sometimes difficult to conclude that the proliferation is due to the presence of phytoestrogens in the plant extract. On the other hand, the yeast two-hybrid assay is associated with steroid hormone receptors and its gene expression including an coactivator, so that the system closely resembles the mammalian hormone system. However, the disadvantage is the potential for false-negative results due to some action via receptors other than ERa, some involve a pathway other than via receptor-mediated gene expression, and some cannot be transported into the cell. 20) Therefore it . Through bioassay-guided separation, the most active compound was demonstrated to be genistein (1), which is known to have potent estrogenic activity, 21) bind to estrogen receptors, 22) induce cell transcription, and elicit biological activities similar to those of natural estrogens. 23) Compound 9, with a 1,1-dimethylallyl group at C-8 in the A ring of genistein (1), showed proliferating activity as potent as that of genistein (1) in MCF-7 cells. Recently, several prenylated flavonoids, such as 6-(1,1-dimethylallyl)-naringenin and 8-prenylnaringenin, have been reported to have strong estrogenic activities, while the parent compound naringenin showed no recognizable estrogenic activity. 24) In a comparison of estrogenic activity between compound 10 (relative cell growth, 112%) and 11 (relative cell growth, 162%), cyclization of a prenyl group in the B-ring was deduced to be important for estrogenic activity.
In the yeast two-hybrid assay, lupinalbin A (4) showed strong estrogenic activity. The compound has an ether bridge between C-2 and C-2Ј, and this bridge formation results in a flat structure, giving a structural similarity to 17b-estradiol.
Isolated compounds showed not only antagonistic activity but also agonistic activity. In particular, prenylated flavonoids have antagonistic activities for both the proliferation of MCF-7 cells and induction of b-galactosidase activity in yeast cells, which were induced by 17b-estradiol. Estrogens act on target tissue by binding to estrogen receptors, which are associated with the ability to promote the proliferation of cells in the breast and uterus, which may increase a woman's risk of breast or uterine cancer. Since some of the isolated flavonoids showed antagonistic activity against 17b-estradiol, these functions may help to reduce the risk of estrogen-mediated cancer and be applicable to clinical trials for breast cancer in postmenopausal women who are treated with estrogen replacement therapy.
Oral administration of compound 1 or 9 caused estrogenic effects in OVX SD rats by increasing their uterine weight, which was evaluated in OVX rats according to the method reported by Miyamoto et al. 25) In contrast to the case of in vitro assays, compound 9 was more effective than genistein (1), which was reported to be converted to dihydrogenistein with less potent estrogenic activity by human intestinal microflora in the gastrointestinal tract. 26, 27) However, compound 9 may be more resistant to degradation by intestinal bacteria due to the presence of a bulky 1,1-dimethylallyl group at C-8 in the A ring of the isoflavone skeleton, which may account for the more potent estrogenic activity of 9 in the in vivo experiment.
In conclusion, we demonstrated that genistein (1) and 8-(1,1-dimethylallyl)genistein (9) were major estrogenic substances in the extract of M. philippinensis, with potent proliferating activity on MCF-7 cells and resulting in a significant increase in uterine weight in OVX rats. Oral administration of 9 showed estrogenic effects stronger than those of 1. In addition, 9 was more antiestrogenic than 1, as shown by the MCF-7 proliferation and b-galactosidase induction in yeast cells, which were stimulated by estradiol. This result shows that 9 may serve as a lead compound for developing preventive and therapeutic agents for various estrogen-mediated diseases. 
